A
nnals of Salcgiru Oncology
会 S p 出 r e g
S
ignificance of herpesvirus entry mediator expression ni human colorectal rveli metastasis
J9umal. Annals of Slurgica Oncology Nanu~Cりpt~［） AS0-2019 明03-0507 .Rl Manu~criprfyp~： laingriO elcitrA
Date Submitte~~~h~r~ 19司May-2019
Complete tsiL ofA1,1tf1ot~ ： aki,Sas i;Yoshiyuk Nara Medical ,yitserivnU Department of Surgery Hokuto, Daisuke; Nara lMedica ,tyirsveniU Depa 比ment o Sfurgery I
n o
ue, Takashi; Nara calMedi ,tysirveniU Department Sfourgery N
oπ,ii Takeo; Nara dicalMe ,tysirveniU Depart 打ent oi f Surgery Y
o
shikawa, Takahiro; Nara Medical ,yitrseivUn Department of Surgery Matsuo, Yasuko; Nara Medical y,itrseivUn Depart 打ient of Surgery Koyama, Fumikazu; Nara Medical y,itservniU Department f Sourgery Sho, Masayuki ; Nara Medical y,itserivUn Department f Sourgery
寓
T o contact the Journ al iffo 仁巴目info @ asoeditorialgro.
寸
P a g e 1f32o
01234567
’89012345678901234567
’89012345678901234567890
123456789111111111122222222223333333333444444444455555555556 A n n a l
s Sfloacigru ygolocnO
S i g n i f i c a n c
e of husvirpeser entηF mediator onsiesprex hniuman latceroloc revil
m e t a s t a s i s
R
unning :eltit HVEM enoisserpx hniuman CRLM
Y o s h i y u k
i ,ikasaS MD; Daisuke ,Hokuto MD, PhD; Thikasa ueIno ，お, PID hD; Takeo
Nomi, MD, PhD; Toirkaha Yoshikawa, MD; Yasuko uo,Mats MD; Fumikazu Koyama,
h⑪，PhD; Masayuki , MoSh D, PhD
D e p a r t m e n
t of Sgeur η，Nara Medical isrevinU 砂， 840 S,ohc-ojih his-raahishaK , Nar α
6 3 4 - 8 5 2 2
, iJαpαn
C
orresponding r:uthoa
D a i s u k
e Hokuto ，乱ID,PhD
D e p a r t m
ent of S,yregru Nara Medical iservniU 匂r, 840 S,ohc-ojih ish-arhaihasK , Nara
6 3 4 - 8 5 2
2 , Japan
P h o n e
: -29-88630744 :xaF 0744 司24-6866
E - m a i l
: edramnaa)to(kuho 圃u.oi.ca
1 T
o
contcat Jehtnruo :ecal iffo o @fnirotideosa grialo.
A n n a l
s Sfloacigru yoglconO eagP 2 fo32
nU2
， 「
42J
凋 『 Pコ ぷ
U7FRUGJnU
句』べ 42Jd
『 Pコ 民
U7
’RUQJnU
唱 ， 、
42JA
『
RJ 点U マJQUQJnuT
目 、
4
「3A
『 Fコ
rO
『／
nOQJnU1
， 、
42JA
『 Fコ
KU
守JQUQJnu
123456789111111111122222222223333333333444444444455555555556
YS, DH, TI, TN, YT, YM, FK, and MS have no ctcilfno of i.tseretn
S y n o p s i s T h i
s tsi fehtsri troper gniyfiralc HVEM enosiesprx hni uman CRLM . High HVEM expniossre was an ientenddepn poor ictsognorp rotcaf OS afrof ret ivel rr.noitcese
CD8+, CD45RO+ tumor gnitartlifni T cslle were syltnacifingi lower tni heh igh HVEM M
C 虹 nr Au
x
2
To tcatnoc the u roJlanf ifoce: nfideos@ao oritial.org
P a g
e 3 fo32
0123456789012345678901234567
・89012345678901234567890
123456789111111111122222222223333333333444444444455555555556 A n n a l
s Slfaocigru ygolocnO
A b s t r a c t
B a
ckground. surivespreH yrtne roatiedm (HVEM) bsha n see detsgegu pot vyal suoira
r o l e
s cnirecna .ygoloib We hvea detroper taht HVEM enoisserpx tniumor sllec si
a s s o c i a t e
d a thiw noitcuder tni neh umber ofgnitartl加ifni-rom esytocphyml and a rpoo
p r o g n o s i
s retfa lacigrus noitceser vnisuoira humanlanitsetniortsag .srecnac The aim of
t h i
s yduts was t cofiral シe chtlacinil ecnacifingis of HVEM enoisserpx hni uman
c o l o r e c t a
l revil sisatsatem (CRLM).
M e
thods. We examined cehtsesa of 14 p0stneita h Ctwi RLM who utwendern evitaruc
l i v e
r noitceser Ntaara alicMed ytisrevinU between 2000 and 2.410 The median
d u r a t i o
n f to fehpu-wolol doirep was 52.0 .hstonm almicchestonohimmuI gniniats was
p e r f o r m e
d gnisu seidobitna tsniaga HVEM, CD4, CDS, and CD45RO.
R e s u l t s
. High HVEM enoisserpx was oedvrseb 4ni9 pstneita )1%7.(4 thiw CRLM.
HVEM enoisserpx was n ato detaicoss thwi ,ega ,redneg aehtnoitartsinimd of
p r e o p e r a t i v
e ,pyraethoemhc tumor ,ezis neht umber fo 加,rsom hrolacigolotsi
d i f f e r e n t i a t i o n
. The hhig HVEM gprou detibihxe yltnacifingis worse llarevo lavivrus
( O S
) naht leht ow HVEM gprou (P=0 ..)200 etairavitluM sisylana delaever taht high
HVEM enoisserpx Cni RLM i asn itendnpeedn or ppo citsongor rotcaf Orof S (I ミH：,53.3
95%CI: 14.1 ,・39.7 06).0=0P isa bsgine d 三7age 0 and hngiav 三5加.srmo The numbers
3 T
o
ctcatno Jehtlanruo iffo臼・o @ ifn a sed oairotigro.l
A n n a l
s Sfloacigru ygloocOn egaP 4 fo32
012345678901234567890123456789012345678901234567
’890
123456789111111111122222222223333333333444444444455555555556
of tartlifni-romu t i n
g CD8+ and CD45RO+ T cslle were syltnacifingi lower tni heh igh
HVEM group nhat tni leh ow HVEM g.puro High HVEM enosisrepx pnirimary
c o l o r e c t a
l rnceca was syltnacifingi detaicossa thwi usronosynch CRLM, utb nto
m e t
achronous CRLM.
C o n c l u s i o n s
. Tumor HVEM eniosesprx might a aypl lacitirc elor CniRLM.
4 T
o
ctcatno th Jenruo olcaiff 巴.nfideosa@o groroit.lai
P a g
e 5 fo32
0123456789012345678901234567
’89012345678901234567890
23456789111111111122222222223333333333444444444455555555556 A n n a l
s Slfaocigru ygolocnO
Background
C o l o r e c t a
l recnac (CRC) tsi tehdrih most common esuac f codetaler-recna
d e a t h
, and t neh umber pofstneita hitw CRC i isgnisaercn orldwidew .]1[latceroloC
l i v e
r sesatsatem (CRLM) have osla become more common, which hsah ad a marked
e f f e c
t on t pehsisongor of CRC [.]4-2 reviL noitceser tneserper s oeht l y cn encha f a o
c u r
e profstneita hitw CRLM. etipesD smentoveimpr snilacigru seuqinhcet and teh
i n t r o d u c t i o
n of new caphermothe y rnsmeieg manddetegrat-ralucelo e rhtapy t, 5eh ・year
s u r v i v a
l setar of pstneita Chtwi RLM aretf citapeh noitceser yldetroper egnar 企om 33 to
6 1
%. Tfoerhe re, nove aleshcoarpp llits d tnee boe devedeplo iotromp ve pehtsisongor
o f
pstneita wiht CRLM. One pyllaitneto ginismrop getarts y i is mmunotherap .y
T u m o r - i n f i l t r a t i n
g lymphocytes )LIT( ceraderedisno cotetubirtno potrymair tsoh
immune p onseser astsniag reves al yptes f mongnaali t加mors [ 6,5 A.] s f Cro RC , wtias
r e p o r t e
d taht pehtceneser of Tllec- n五lisetart pnirima cyrnool tumor s wa asdetaicoss
wi bhtrette ovellar lavivrus (OS) 7, 8[ F.] orrmhertu a,en astaicos ion between an
i n c r e a s e
d number of TIL i Cn RLM and irovedmp OS h bsa een detroper 9, 1[.]0
Howe,rev tsasmoru a have yteirav f moechanisms evarof ngid immune snopser es, eht
c l i n i c a
l i caffe cy of immunoth eryap agan st i CRC i vers lydetimi 1 , 1[ 12] R ec. ltne y,
i m m u n o t h e r a p
y csah dhange lrkedma y whti iehtudortn ctnoi cofntiopkceh otibihni rs,
5
To ontc ttcahe aJnruo l o仔: ieicnfo@ae dios o rtial.org
